Charles River Laboratories Intl. Inc vs Occidental Petroleum Corporation — how do they compare? Charles River Laboratories Intl. Inc trades at $303.91 (market cap $14.23B), while Occidental Petroleum Corporation trades at $60.58 (market cap $60.26B). The key difference: Occidental Petroleum Corporation is far larger — about 4.2× Charles River Laboratories Intl. Inc's market cap, and Occidental Petroleum Corporation pays a 1.86% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Occidental Petroleum Corporation for 92 Days on average.
| CRL | OXY | |
|---|---|---|
Market Cap | $14.23B | $60.26B |
Volume | 1,176,885 | 11,718,920 |
Sector | Health | Energy |
52-Week High | $310.77 | $66.24 |
52-Week Low | $149.93 | $38.92 |
Typical Hold Time | 33 Days | 92 Days |
Enterprise Value | $17.06B | $79.02B |
Dividend Yield | — | 1.86% |
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
Occidental Petroleum (OXY) trades at $60.52, up 3.97% in the last session, with a bullish technical signal from moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.40 surpassing the $1.83 expectation. Financial health is supported by a strong net income margin of 30.32% and an ROE of 21.46%, though revenue has declined from $36.6B in 2022 to $21.6B in 2025. Analyst consensus is a Buy with a $71.40 price target, and a dividend of $0.28 is scheduled for payment in October 2026.
OXY presents a positive outlook driven by earnings beats, debt reduction efforts, and analyst optimism, but faces risks from volatile oil prices and declining revenue trends. Investment appeal hinges on execution of cash flow targets and oil market stability, with current valuation metrics like a P/E of 17.78 appearing reasonable relative to growth prospects.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →